Aldoro Resources unveils a solid maiden JORC Resource estimate

Nick Sundich Nick Sundich, October 12, 2022

Rubidium and lithium explorer Aldoro Resources (ASX:ARN) gave its shareholders a hint of just how much lithium and rubidium there might be at its Niobe project in Western Australia. The company provided a maiden Inferred JORC Mineral Resource estimate, a move which pleased shareholders this morning. But there is more work to do. 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Aldoro Resources might have something in Niobe 

The maiden Inferred JORC Mineral Resource estimate is 4.6Mt of lithium at 0.07% lithium and 0.17% rubidium. This is equivalent to 8,060 contained tonnes of rubidium and 3,080 tonnes of lithium.

Obviously, lithium is a hot commodity right now, but it hasn’t got the biggest resource there. Still, Aldoro Resources claims to have one of the highest-grade undeveloped rubidium deposits globally. Rubidium is an industrial mineral that has several applications, including night vision gear, GPS systems and fibre optic cables.

 

More work to do 

Aldoro Resources shareholders shouldn’t get too ahead of themselves, though. This was only an estimate and was only Inferred (a lower level of confidence than Indicated). This morning’s announcement admitted that more work is required to enable the estimate to move from Inferred to Indicated. 

Nevertheless, the company has commenced a development feasibility study and another drilling campaign to grow the resource size and upgrade the classification. And shareholders can be proud that it has delivered this within just 12 months of acquiring the tenement license. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): Its taken the plunge into a Phase 2 trial against T-Cell Lymphoma

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…

Botanix Pharmaceuticals

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this…

beat the market

How can an investor beat the market? Here’s how to go about it

You may’ve heard the expression to ‘beat the market’. What does this mean? Well, it depends on the context in…